Fig. 5

Overview of patients (%) achieving 2-h pain freedom in ubrogepant phase III clinical trials. *ACHIEVE I; 50 mg vs. placebo, p = 0.0023; 100 mg vs. placebo, p = 0.0003. ACHIEVE II; 25 mg vs. placebo, p = 0.0285; 50 mg vs. placebo, p = 0.0129